Overview
The primary objective of this study is to assess the safety and tolerability of AMG 513 after single and multiple doses.
Eligibility
Inclusion Criteria:
- Participants in the study will be males and females 18 to 65 years of age at the time of signing the informed consent with a body mass index (BMI) between ≥ 30 kg/m^2 and ≤ 40 kg/m^2.
- Females enrolled must be of non-childbearing potential.
Exclusion Criteria:
- History and/or clinical evidence of diabetes mellitus, including hemoglobin A1c ≥ 6.5% and/or a fasting glucose of ≥ 126 mg/dL (7 mmol/L) at screening.
- Triglycerides ≥ 5.65 mmol/L (i.e., 500 mg/dL) at screening.